Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice. - Wikidata - wikimedia - TriplyDB

Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.

Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.

http://www.wikidata.org/entity/Q50903830

about

An Update on the Effect of Incretin-Based Therapies on β-Cell Function and Mass Extended exenatide administration enhances lipid metabolism and exacerbates pancreatic injury in mice on a high fat, high carbohydrate diet Glucagon-like peptide-1 receptor agonist Liraglutide has anabolic bone effects in ovariectomized rats without diabetes Effects of Noise Exposure on Systemic and Tissue-Level Markers of Glucose Homeostasis and Insulin Resistance in Male Mice Divergent effects of liraglutide, exendin-4, and sitagliptin on beta-cell mass and indicators of pancreatitis in a mouse model of hyperglycaemia Effects of the glucagon-like peptide-1 receptor agonist liraglutide in juvenile transgenic pigs modeling a pre-diabetic condition PKA Enhances the Acute Insulin Response Leading to the Restoration of Glucose Control.Pancreatic alpha-cells from female mice undergo morphofunctional changes during compensatory adaptations of the endocrine pancreas to diet-induced obesity.Adverse drug reactions associated with the use of liraglutide in patients with type 2 diabetes--focus on pancreatitis and pancreas cancer.Rb and p107 are required for alpha cell survival, beta cell cycle control and glucagon-like peptide-1 action.GLP-1 based therapies: clinical implications for gastroenterologists.Glucagon-like peptide-1 receptor agonist exendin-4 protects against interleukin-1β-mediated inhibition of glucose-stimulated insulin secretion by mouse insulinoma β cells.Improvement of islet graft function using liraglutide is correlated with its anti-inflammatory properties.Mouse insulin cells expressing an inducible RIPCre transgene are functionally impaired.Long-term ketogenic diet causes glucose intolerance and reduced β- and α-cell mass but no weight loss in mice.Effects of liraglutide in hypothalamic arcuate nucleus of obese mice.Incretin Therapies Do Not Expand β-Cell Mass or Alter Pancreatic Histology in Young Male Mice.Molecular and cellular mechanisms of glucagon-like peptide-1 receptor agonist-mediated attenuation of cardiac fibrosis.Distinct effects of dipeptidyl peptidase-4 inhibitor and glucagon-like peptide-1 receptor agonist on islet morphology and function.

P2860

Q26749089-45AF22DA-EEC5-4367-A4E2-DB4BD396DD63 Q27339590-73D54411-6B39-49BD-B725-58D46C69695A Q28546539-678A1565-5944-42AA-BC49-E568FA9B1A9D Q30374509-2BE10F56-6BC6-4FFE-AEA9-38B845B07AF6 Q34041974-FE3FBD49-A402-45CC-80C9-635F7CA780CA Q35184904-6B2B3278-B294-40F9-BCA6-49DF4C8C40F3 Q35532241-CB7B5819-322E-4965-A406-59BE7F959003 Q36293504-1A143025-8B55-42BA-93CE-5DBA64545EA7 Q38264360-2E5F0B7C-0E8D-4A2D-B396-6F0429DA6B04 Q38447564-11E0BF51-FEA3-41C7-AF4B-E161730CB193 Q38703292-4C760EDE-8786-41E4-B43F-BE3ACB389996 Q41692104-65AA7375-E16B-4180-BC51-C76B4118C5EF Q42364488-DCC40D7C-F1BE-4890-91BA-B6AD465E0972 Q43134944-C022B705-FC96-4718-879B-5D944D0A05B9 Q47190341-3C46FA00-5C66-45AB-8384-2FEA0313753F Q48877643-B27DF53A-D891-4D53-BD48-CEEAA7049E91 Q52780711-F8965432-A407-40F5-8B8C-8F4961E147FF Q53337186-A6B856A7-6730-4A79-9506-28C4C8C3CDA8 Q53352969-7BEDF94C-EE81-4274-A72F-9846377E3378

P2860

Glucagon-like peptide-1 receptor agonist treatment reduces beta cell mass in normoglycaemic mice.

http://www.wikidata.org/entity/Q50903830

description

2013 nî lūn-bûn

@nan

2013年の論文

@ja

2013年学术文章

@wuu

2013年学术文章

@zh

2013年学术文章

@zh-cn

2013年学术文章

@zh-hans

2013年学术文章

@zh-my

2013年学术文章

@zh-sg

2013年學術文章

@yue

2013年學術文章

@zh-hant

name

Glucagon-like peptide-1 recept ...... l mass in normoglycaemic mice.

@en

Glucagon-like peptide-1 recept ...... l mass in normoglycaemic mice.

@nl

type

label

Glucagon-like peptide-1 recept ...... l mass in normoglycaemic mice.

@en

Glucagon-like peptide-1 recept ...... l mass in normoglycaemic mice.

@nl

prefLabel

Glucagon-like peptide-1 recept ...... l mass in normoglycaemic mice.

@en

Glucagon-like peptide-1 recept ...... l mass in normoglycaemic mice.

@nl

P1433

Q50903830-5E7E1F28-0105-4BA6-97C2-0F119935F851

P1476

Q50903830-77D8BC72-BB68-4E22-816B-315CF90C3DC3

P2093

Q50903830-305D5F62-765E-4B34-A720-9B10B11725A4

Q50903830-6E016801-35B1-45F1-9DE6-0FD4948BC0D8

Q50903830-7184DC70-6949-4A7B-BB7A-C7957D9403A4

Q50903830-822C6BE5-632D-4C49-9F5E-B9E4BDF7865A

Q50903830-9A9A3127-5DEB-4893-8969-B75DAB887C08

Q50903830-F8CFAB83-E78F-4AAB-AC82-0881D9C0D803

P2860

Q50903830-02C01E27-CAB7-452E-BFDD-E07D1DE37CC7

Q50903830-1517890E-EE10-40C8-8036-B7610FFD8757

Q50903830-26F5A5F2-4C25-4374-9C57-A6A77CB3A0F6

Q50903830-27066719-08C6-4F19-8507-B99C8A4E1B78

Q50903830-2D5DFC52-97F9-4B8E-A002-45DF7E748DA6

Q50903830-3D85A7B6-AA54-4CFF-AA4E-B507EF1BAAC1

Q50903830-3E007725-6C11-4A1C-AFD1-5B5F94271CAF

Q50903830-4517968B-EFE5-42E8-9C51-A5AA590BA46E

Q50903830-5C7FB34E-539D-4A31-97DB-4AB140C4037E

Q50903830-6363E516-8A44-46C2-AA00-D65F553A70F1

P2888

Q50903830-A5BC0BFF-41E9-4FB3-8CF8-8E86525802CF

P304

Q50903830-CE2395D7-9E64-4C40-BFB7-07E7AF9FE49F

P31

Q50903830-4002C55A-3A82-48DE-A840-0C98920AE110

P356

Q50903830-ABFF847A-F90D-4EF9-B063-A8D59D68520E

P433

Q50903830-3CCE4544-89A5-424C-A0F0-4E645E10474C

P478

Q50903830-9DCA165C-7BC0-4C80-9D82-E4111E52B444

P50

Q50903830-0F892D07-D2C9-4EA7-8162-5A195D7A3510

Q50903830-3BD1818E-9C9B-459E-8899-D2EBD21186DE

P577

Q50903830-161FDD7B-0A15-46AA-A0C8-406381D4B4CD

P698

Q50903830-74208D24-A835-4B6A-8D6E-8BC614DC34DE

P356

S00125-013-2957-2

P1433

P1476

Glucagon-like peptide-1 recept ...... l mass in normoglycaemic mice.

@en

P2093

E J P de Koning

http://www.w3.org/2001/XMLSchema#string

H A M Töns

http://www.w3.org/2001/XMLSchema#string

J H Ellenbroek

http://www.w3.org/2001/XMLSchema#string

M A Hanegraaf

http://www.w3.org/2001/XMLSchema#string

M J A Westerouen van Meeteren

http://www.w3.org/2001/XMLSchema#string

N de Graaf

http://www.w3.org/2001/XMLSchema#string

P2860

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

GLP-1 receptor activated insulin secretion from pancreatic β-cells: mechanism and glucose dependence

The Physiology of Glucagon-like Peptide 1

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

Mechanisms linking obesity to insulin resistance and type 2 diabetes

Chronic GLP-1 receptor activation by exendin-4 induces expansion of pancreatic duct glands in rats and accelerates formation of dysplastic lesions and chronic pancreatitis in the Kras(G12D) mouse model.

Effects of exenatide and lifestyle modification on body weight and glucose tolerance in obese subjects with and without pre-diabetes

Exendin-4 improves blood glucose control in both young and aging normal non-diabetic mice, possible contribution of beta cell independent effects.

Perspective: Postnatal pancreatic beta cell growth.

Glucagonlike peptide 1-based therapies and risk of hospitalization for acute pancreatitis in type 2 diabetes mellitus: a population-based matched case-control study.

P2888

s00125-013-2957-2

P304

1980-1986

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1007/S00125-013-2957-2

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

56

http://www.w3.org/2001/XMLSchema#string

P50

Françoise Carlotti

P577

2013-06-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23771206

http://www.w3.org/2001/XMLSchema#string